"id","rationale","description","label","instanceType","name","uuid:ID"
"StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","StudyDesign","Study Design 1","524d0fa9-0a68-436d-8f51-a596e99d0bc8"
